Background: Radiotherapy is the primary treatment modality for several cancers including prostate cancer where approximately 50% of men are treated with curative intent. However, around 20-30% of men (~3,500 per year in UK) with intermediate- to high-risk disease experience treatment failure. Additionally, radiotherapy can also result in damage to neighbouring healthy tissue including the bladder and bowel, severely impacting patient quality of life.
Technology: Gold nanoparticles act as potent radiosensitisers, making tumour cells more susceptible to the killing effects of radiotherapy. By enhancing radiation dose in the localised vicinity of the nanoparticle, they limit the potential for additional damage to the surrounding normal and healthy tissue.
BXTA Nanotherapy Ltd was founded in 2023 as a joint venture between BXTAccelyon Ltd (BXTA) and QUBIS, with the primary aim of advancing the development, regulatory approval, and commercialisation of our lead nanoparticle formulation termed AuX2R. This innovative nanotherapeutic combines the physical effects of gold with propriety molecular targeting to enhance tumour cell sensitivity to radiotherapy. AuX2R has undergone substantial pre-clinical development and is positioned to enter clinical investigation.
Visit website